Concepedia

Pushkal Garg

PG

Statistics

Publications

34

Citations

9.3K

H-Index

28

Active since

1990

Affiliations

Alnylam Pharmaceuticals (United States)(Current)

University College London

Johns Hopkins University

Brigham and Women's Hospital

Bicêtre Hospital

Pushkal Garg is an author at Alnylam Pharmaceuticals (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Publications per year

1990–2024

34

Publications

34

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

David Adams, Alejandra González‐Duarte, William O’Riordan et al. · New England Journal of Medicine · 2018 · 2.9K citations · Full text

, , +14

A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)

Flavio Vincenti, B Charpentier, Yves Vanrenterghem et al. · American Journal of Transplantation · 2010 · 946 citations

, , +15

Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria

Manisha Balwani, Eliane Sardh, Paolo Ventura et al. · New England Journal of Medicine · 2020 · 592 citations · Full text

, , +14

Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)

Antoine Dürrbach, JO Medina Pestana, Thomas C. Pearson et al. · American Journal of Transplantation · 2010 · 565 citations · Full text

, , +17

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

Sander F. Garrelfs, Yaacov Frishberg, Sally A. Hulton et al. · New England Journal of Medicine · 2021 · 495 citations · Full text

, , +10

1–5 of 34